Drug Approval | January 25, 2023
Granules Pharmaceuticals receives ANDA approval for amphetamine mixed salts ER capsules
Granules now have a total of 53 ANDA approvals from USFDA
Granules now have a total of 53 ANDA approvals from USFDA
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%
Swiftmelt 1515-I meets performance requirements and secures skin attachment
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
Acquisitions have the potential to add at least $1 billion in sales by 2028
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Subscribe To Our Newsletter & Stay Updated
